venBio Partners

Latest statistics and disclosures from venBio Partners's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are ALXO, HRMY, AKRO, CMPI, APLS, and represent 97.75% of venBio Partners's stock portfolio.
  • Reduced shares in these 2 stocks: DTIL (-$8.0M), APLS.
  • Sold out of its positions in DTIL.
  • venBio Partners was a net seller of stock by $-8.6M.
  • venBio Partners has $1.1B in assets under management (AUM), dropping by 72.18%.
  • Central Index Key (CIK): 0001776382

Tip: Access up to 7 years of quarterly data

Positions held by venBio Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for venBio Partners

Companies in the venBio Partners portfolio as of the December 2020 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Alx Oncology Hldgs (ALXO) 73.8 $836M 9.7M 86.20
Harmony Biosciences Hldgs In (HRMY) 11.2 $127M 3.5M 36.15
Akero Therapeutics (AKRO) 5.6 $63M 2.4M 25.80
Checkmate Pharmaceuticals In (CMPI) 4.7 $54M 3.7M 14.59
Apellis Pharmaceuticals (APLS) 2.5 $28M -2% 491k 57.20
Metacrine Ord (MTCR) 2.1 $24M 3.1M 7.86
Verona Pharma Sponsored Ads (VRNA) 0.1 $1.4M 199k 7.00

Past Filings by venBio Partners

SEC 13F filings are viewable for venBio Partners going back to 2019